Early colour Doppler duct diameter and symptomatic patent ductus arteriosus in a cyclo-oxygenase inhibitor naïve population

Anne Marie Heuchan, David Young

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

AIMS: To examine the relationship between early duct diameter and patent ductus arteriosus (PDA) symptoms.

METHODS: A retrospective study of infants <29 weeks of gestation with early colour Doppler assessment of PDA diameter, in whom PDA was managed conservatively, without cyclo-oxygenase inhibitor (COI) treatment.

RESULTS: Gestation and birthweight, [median (range)], were 26 (23-28) weeks and 865 (500-1440) g, respectively. Symptomatic PDA developed in 20 (68.9%) infants, with 11 (37.9%) referred for PDA ligation at 24 (17-30) days. Symptoms resolved spontaneously in 7 infants (24.1%) at 19 (7-32) days. There were 6 (20.7%) deaths, including four early neonatal deaths with large PDA. Early colour Doppler PDA diameter >1.5 mm (n = 20) predicted development of symptomatic PDA (sensitivity 91%, specificity 100%), but symptoms resolved spontaneously without treatment in 30%. There was a significant linear correlation (p < 0.001) with increasing early PDA diameter and the development of more persistent PDA symptoms, early neonatal mortality and morbidity.

CONCLUSIONS: In our (COI)-naïve population, the mortality and morbidity associated with prolonged exposure to unrestricted ducts are high. Not all infants with early PDA diameter >1.5 mm have persistent symptomatic PDA, but early PDA diameter could be utilized to identify those infants at greatest risk of adverse outcome associated with PDA.

LanguageEnglish
Pages254-257
Number of pages4
JournalActa Paediatrica
Volume102
Issue number3
Early online date4 Jan 2013
DOIs
Publication statusPublished - 31 Mar 2013

Fingerprint

Patent Ductus Arteriosus
Cyclooxygenase Inhibitors
Color
Population
Morbidity
Pregnancy
Infant Mortality
Ligation

Keywords

  • cyclo-oxygenase inhibitors (COIs)
  • echocardiography
  • patent ductus arteriosus (PDA)
  • PDA ligation
  • premature

Cite this

@article{220562e02a844cc9b3c18cabb5870561,
title = "Early colour Doppler duct diameter and symptomatic patent ductus arteriosus in a cyclo-oxygenase inhibitor na{\"i}ve population",
abstract = "AIMS: To examine the relationship between early duct diameter and patent ductus arteriosus (PDA) symptoms. METHODS: A retrospective study of infants <29 weeks of gestation with early colour Doppler assessment of PDA diameter, in whom PDA was managed conservatively, without cyclo-oxygenase inhibitor (COI) treatment. RESULTS: Gestation and birthweight, [median (range)], were 26 (23-28) weeks and 865 (500-1440) g, respectively. Symptomatic PDA developed in 20 (68.9{\%}) infants, with 11 (37.9{\%}) referred for PDA ligation at 24 (17-30) days. Symptoms resolved spontaneously in 7 infants (24.1{\%}) at 19 (7-32) days. There were 6 (20.7{\%}) deaths, including four early neonatal deaths with large PDA. Early colour Doppler PDA diameter >1.5 mm (n = 20) predicted development of symptomatic PDA (sensitivity 91{\%}, specificity 100{\%}), but symptoms resolved spontaneously without treatment in 30{\%}. There was a significant linear correlation (p < 0.001) with increasing early PDA diameter and the development of more persistent PDA symptoms, early neonatal mortality and morbidity. CONCLUSIONS: In our (COI)-na{\"i}ve population, the mortality and morbidity associated with prolonged exposure to unrestricted ducts are high. Not all infants with early PDA diameter >1.5 mm have persistent symptomatic PDA, but early PDA diameter could be utilized to identify those infants at greatest risk of adverse outcome associated with PDA.",
keywords = "cyclo-oxygenase inhibitors (COIs), echocardiography, patent ductus arteriosus (PDA), PDA ligation , premature",
author = "Heuchan, {Anne Marie} and David Young",
year = "2013",
month = "3",
day = "31",
doi = "10.1111/apa.12103",
language = "English",
volume = "102",
pages = "254--257",
journal = "Acta Paediatrica",
issn = "0803-5253",
number = "3",

}

Early colour Doppler duct diameter and symptomatic patent ductus arteriosus in a cyclo-oxygenase inhibitor naïve population. / Heuchan, Anne Marie; Young, David.

In: Acta Paediatrica, Vol. 102, No. 3, 31.03.2013, p. 254-257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early colour Doppler duct diameter and symptomatic patent ductus arteriosus in a cyclo-oxygenase inhibitor naïve population

AU - Heuchan, Anne Marie

AU - Young, David

PY - 2013/3/31

Y1 - 2013/3/31

N2 - AIMS: To examine the relationship between early duct diameter and patent ductus arteriosus (PDA) symptoms. METHODS: A retrospective study of infants <29 weeks of gestation with early colour Doppler assessment of PDA diameter, in whom PDA was managed conservatively, without cyclo-oxygenase inhibitor (COI) treatment. RESULTS: Gestation and birthweight, [median (range)], were 26 (23-28) weeks and 865 (500-1440) g, respectively. Symptomatic PDA developed in 20 (68.9%) infants, with 11 (37.9%) referred for PDA ligation at 24 (17-30) days. Symptoms resolved spontaneously in 7 infants (24.1%) at 19 (7-32) days. There were 6 (20.7%) deaths, including four early neonatal deaths with large PDA. Early colour Doppler PDA diameter >1.5 mm (n = 20) predicted development of symptomatic PDA (sensitivity 91%, specificity 100%), but symptoms resolved spontaneously without treatment in 30%. There was a significant linear correlation (p < 0.001) with increasing early PDA diameter and the development of more persistent PDA symptoms, early neonatal mortality and morbidity. CONCLUSIONS: In our (COI)-naïve population, the mortality and morbidity associated with prolonged exposure to unrestricted ducts are high. Not all infants with early PDA diameter >1.5 mm have persistent symptomatic PDA, but early PDA diameter could be utilized to identify those infants at greatest risk of adverse outcome associated with PDA.

AB - AIMS: To examine the relationship between early duct diameter and patent ductus arteriosus (PDA) symptoms. METHODS: A retrospective study of infants <29 weeks of gestation with early colour Doppler assessment of PDA diameter, in whom PDA was managed conservatively, without cyclo-oxygenase inhibitor (COI) treatment. RESULTS: Gestation and birthweight, [median (range)], were 26 (23-28) weeks and 865 (500-1440) g, respectively. Symptomatic PDA developed in 20 (68.9%) infants, with 11 (37.9%) referred for PDA ligation at 24 (17-30) days. Symptoms resolved spontaneously in 7 infants (24.1%) at 19 (7-32) days. There were 6 (20.7%) deaths, including four early neonatal deaths with large PDA. Early colour Doppler PDA diameter >1.5 mm (n = 20) predicted development of symptomatic PDA (sensitivity 91%, specificity 100%), but symptoms resolved spontaneously without treatment in 30%. There was a significant linear correlation (p < 0.001) with increasing early PDA diameter and the development of more persistent PDA symptoms, early neonatal mortality and morbidity. CONCLUSIONS: In our (COI)-naïve population, the mortality and morbidity associated with prolonged exposure to unrestricted ducts are high. Not all infants with early PDA diameter >1.5 mm have persistent symptomatic PDA, but early PDA diameter could be utilized to identify those infants at greatest risk of adverse outcome associated with PDA.

KW - cyclo-oxygenase inhibitors (COIs)

KW - echocardiography

KW - patent ductus arteriosus (PDA)

KW - PDA ligation

KW - premature

UR - http://www.scopus.com/inward/record.url?scp=84873412042&partnerID=8YFLogxK

U2 - 10.1111/apa.12103

DO - 10.1111/apa.12103

M3 - Article

VL - 102

SP - 254

EP - 257

JO - Acta Paediatrica

T2 - Acta Paediatrica

JF - Acta Paediatrica

SN - 0803-5253

IS - 3

ER -